INNOVATE (NYSE:VATE – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($2.18) by $1.60, FiscalAI reports. The business had revenue of $382.70 million during the quarter, compared to analysts’ expectations of $251.70 million.
Here are the key takeaways from INNOVATE’s conference call:
- INNOVATE reported Q4 revenue of $382.7 million and adjusted EBITDA of $24.5 million (FY 2025 revenue $1.2 billion, adjusted EBITDA $67.2 million), and narrowed net loss to $7.8 million, showing overall improvement in top-line and profitability versus prior year.
- Infrastructure (DBM Global) was the primary growth driver with Q4 revenue of $373.9 million, adjusted EBITDA of $28 million, and an adjusted backlog increase of about $700 million to just over $1.8 billion, though gross margin compressed ~350 bps year‑over‑year.
- Life sciences milestone—FDA approval of MediBeacon’s next‑generation TGFR system plus a high‑profile JASN Editor’s Choice publication and early China commercialization support commercial momentum, including the first TGFR order and a U.S. Centers of Excellence rollout.
- R2 finished 2025 with record full‑year revenue of $12.5 million, stronger international sales and an ~80‑unit backlog plus a China distribution commitment for 600 systems over three years, but Q4 sales were hampered by inventory constraints and the business is seeking external capital.
- INNOVATE is pursuing asset sales and lender negotiations to address capital structure; while cash rose to $112.1 million (from $48.8M), consolidated debt increased to $687.2 million, posing continued leverage and restructuring risk.
INNOVATE Price Performance
INNOVATE stock opened at $4.61 on Friday. The stock has a market cap of $62.90 million, a price-to-earnings ratio of -0.95 and a beta of 1.63. The firm has a 50-day moving average of $5.02 and a two-hundred day moving average of $5.00. INNOVATE has a 1 year low of $3.75 and a 1 year high of $8.52.
Institutional Trading of INNOVATE
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INNOVATE in a report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, INNOVATE has a consensus rating of “Sell”.
View Our Latest Report on INNOVATE
About INNOVATE
INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; and 3-D building information modeling and detailing for commercial, industrial, and infrastructure construction projects, such as buildings and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, metal processing, refineries, pulp and paper mills, and power plants.
Further Reading
Receive News & Ratings for INNOVATE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INNOVATE and related companies with MarketBeat.com's FREE daily email newsletter.
